

Table of Contents

1	Introduction	9
1.1	Background.....	10
1.2	Purpose and Objectives.....	11
1.3	Scope.....	11
1.4	Structure of the Guide.....	12
2	RNA-Based Therapeutics	15
2.1	Introduction	15
2.2	RNA Types and Characteristics	15
2.3	Concepts.....	18
2.4	RNA Medicinal Products	19
3	Regulatory.....	21
3.1	Introduction	21
3.2	Classification of mRNA Drug Products (DPs)	21
4	RNA Risk Profile	25
4.1	Introduction	25
4.2	Facility Design and Operation.....	25
4.3	Risk Identification.....	26
4.4	RNA-Specific Risks.....	27
4.5	Common Facility Associated Risks	29
4.6	Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs).....	31
5	RNA Manufacturing Process	33
5.1	Introduction	33
5.2	Overview of DNA Template	35
5.3	Enzymatic Reactions	36
5.4	RNA Purification.....	40
5.5	RNA Formulation (Bulk Drug Product).....	42
5.6	RNA Quality Control.....	43
5.7	Process Control Strategy	45
5.8	Synthesis Rate and Production Scheduling.....	46
5.9	Economic Aspects.....	48
6	Facility Design Considerations.....	51
6.1	Introduction	51
6.2	Design Planning Requirements and Best Practice	51
6.3	GMP Requirements	53
6.4	Safety Aspects and Exposure Levels/Containment Facility Implications	55
6.5	Production Scale.....	58
6.6	Unique Facility Features	60
6.7	Equipment Design.....	63
6.8	Utility Design	71

7	Manufacturing Networks	75
7.1	Introduction	75
7.2	Manufacturing Concepts	75
7.3	Traditional Central Facilities	77
7.4	Pandemic-Ready Network	79
7.5	Distributed Manufacturing Initiatives	81
7.6	Modular, Point-of-Care mRNA Manufacturing Using Small-Footprint Equipment	83
8	Advanced Technologies	85
8.1	Introduction	85
8.2	Advances in Manufacture, Supply Chain and Drug Delivery	85
8.3	Advanced Process Technologies	86
8.4	Advanced Analytical Technologies	94
8.5	Prospective Future Applications of RNA	101
8.6	Outlook	102
9	Appendix 1 – Production Cost Estimate	103
9.1	Introduction	103
10	Appendix 2 – References	111
11	Appendix 3 – Glossary	127
11.1	Acronyms and Abbreviations	127
11.2	Definitions	132